Drugs / Ofirnoflast
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07172867 | Jan 2026 | obesity disorder, type 2 diabetes mellitus | Halia Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT07052006 | Dec 2023 → Jan 2026 overdue | myelodysplastic syndrome | Halia Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05447546 Comparator | Jun 2022 → Jul 2023 | — | Halia Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06241742 Comparator | Feb → Apr 2024 | — | Halia Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ofirnoflast | “Ofirnoflast (HT-6184) and Semaglutide in Obese or Overweight Participants With Type 2 Diabetes Mellitus (T2DM)” NCT07172867 ↗ |
| Known as | HT-6184 | “Ofirnoflast (HT-6184) and Semaglutide in Obese or Overweight Participants With Type 2 Diabetes Mellitus (T2DM)” NCT07172867 ↗ |
| Modality | Small molecule | — CHEMBL5750400 ↗ |
| Route | Oral | “administered as single oral doses” NCT05447546 ↗ |